PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, has announced that patients in Poland received the first doses of PYLCLARI��(INN. Piflufolastat (18F) also known as 18F-DCFPyL) ... .
“Europe is not backing down ... The long-planned mixed-use project on the site of the former CuriumPalace hotel in Limassol is advancing towards licensing, with authorities yet to finalise key planning and building permits, industry sources say ... ....
The long-planned mixed-use project on the site of the former CuriumPalace hotel in Limassol is advancing towards licensing, with authorities yet to finalise key planning and building permits, industry sources say ... ....
Kirkland & Ellis is advising CapVest Partners on the recapitalization of Curium Pharma, a leading producer of radiopharmaceuticals, via a new continuation vehicle (CV) ... CapVest will remain the controlling shareholder of Curium.
) CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally ... The CV values Curium at circa $7 billion, representing the largest transaction in nuclear medicine globally.
The Faculty of Medicine together and the TurkuPETCentre hosted visitors from the radiopharmaceutical company Curium Pharma to showcase research and innovation in Turku region ...Feedback from Curium was highly positive..